Iqbal J Hussain
CIK 1862050 · Chief Legal Officer · last filed 2026-06-24
Iqbal J Hussain is a Chief Legal Officer who has filed 49 SEC Form 4 insider transactions across 1 company since 2021. The most recent filing, for CNTA, was dated Jun 24, 2026. Across all open-market trades the lifetime net is −$4.1M, making them a net seller over the disclosed history. 15 Form 144 notices of planned sales are also on file; the latest, for Centessa Pharmaceuticals on Jan 30, 2026, lists the filer as an officer. 15 sales listed on those notices, worth $3.3M in all, have no matching Form 4.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CNTA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS
CAMBRIDGE, X0 CB22 3FH
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Chief Legal Officer | 0 | $40.50 | $0 | -$4.15M | 34 | 2026-06-24 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| CNTA | Direct | 0 | — | 2026-06-24 |
| By spouse | 0 | — | 2026-06-24 | |
| Total | 0 |
Recent Filings
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | Centessa Pharmaceuticals plc (CNTA) Delisted | Disp (D) | −123,145 | $0 | EDGAR |
| 2026-02-03 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | +12,259 | -$1.20M | EDGAR |
| 2026-01-30 | Centessa Pharmaceuticals | Notice (144) Officer · Planned Jan 30, 2026 No sale on file |
−39,961 | -$1.02M | EDGAR |
| 2025-11-18 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Sep 14, 2024 |
— | -$130.8K | EDGAR |
| 2025-11-17 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Nov 17, 2025 · 10b5-1 plan Sold: listed on the Jan 30, 2026 notice |
−6,000 | -$166.4K | EDGAR |
| 2025-10-16 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Sep 14, 2024 |
— | -$99.4K | EDGAR |
| 2025-10-15 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Oct 15, 2025 · 10b5-1 plan Sold: listed on the Nov 17, 2025 notice |
−6,000 | -$135.7K | EDGAR |
| 2025-09-15 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Sep 15, 2025 · 10b5-1 plan Sold: listed on the Oct 15, 2025 notice |
−6,000 | -$130.9K | EDGAR |
| 2025-09-15 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Sep 14, 2024 |
— | -$96.1K | EDGAR |
| 2025-09-11 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Sep 14, 2024 |
— | -$606.5K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).
Sales Reported Only on Form 144
15 sales · $3.28M| Sold | Symbol | Shares | Proceeds | Avg Price | Listed On |
|---|---|---|---|---|---|
| 2025-11-17 | Centessa Pharmaceuticals | 6,000 | $165.8K | $27.64 | 2026-01-30 |
| 2025-10-15 | Centessa Pharmaceuticals plc | 6,000 | $134.4K | $22.41 | 2025-11-17 |
| 2025-09-15 | Centessa Pharmaceuticals plc | 6,000 | $131.1K | $21.85 | 2025-10-15 |
| 2025-09-10 | Centessa Pharmaceuticals plc | 20,000 | $440.0K | $22.00 | 2025-09-15 |
| 2025-09-09 | Centessa Pharmaceuticals plc | 20,000 | $400.1K | $20.01 | 2025-09-10 |
| 2025-08-15 | Centessa Pharmaceuticals plc | 6,000 | $103.4K | $17.23 | 2025-09-09 |
| 2025-07-15 | Centessa Pharmaceuticals plc | 6,000 | $89.6K | $14.93 | 2025-08-15 |
| 2025-06-24 | Centessa Pharmaceuticals plc | 12,000 | $168.2K | $14.02 | 2025-07-15 |
| 2025-05-01 | Centessa Pharmaceuticals plc | 311 | $4.4K | $14.00 | 2025-06-24 |
| 2025-04-28 | Centessa Pharmaceuticals plc | 2,080 | $29.1K | $14.01 | 2025-06-24 |
| 2025-04-25 | Centessa Pharmaceuticals plc | 3,609 | $50.5K | $14.00 | 2025-04-28 |
| 2025-03-17 | Centessa Pharmaceuticals plc | 6,000 | $98.7K | $16.45 | 2025-04-25 |
| 2025-02-18 | Centessa Pharmaceuticals plc | 6,000 | $97.1K | $16.18 | 2025-03-17 |
| 2025-01-15 | Centessa Pharmaceuticals plc | 6,000 | $91.7K | $15.29 | 2025-02-18 |
| 2024-12-16 | Centessa Pharmaceuticals plc | 77,705 | $1.27M | $16.39 | 2025-01-15 |